Bridging the gap between experimental animals and humans in osteosarcoma

Cancer Treatment and Research

Volumn 152, Issue , 2009, Pages 439-446

  Withrow, Stephen J ^a   Khanna, Chand ^b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EZRIN; MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PLATINUM COMPLEX; PROTEIN P53; RETINOBLASTOMA PROTEIN; SAMARIUM; SCATTER FACTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CONFERENCE PAPER; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LIMB AMPUTATION; LIMB SALVAGE; LYMPH NODE METASTASIS; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; STEREOTACTIC RADIOSURGERY; ANIMAL; BONE NEOPLASMS; DOG; DOG DISEASES; DOMESTIC ANIMAL; GENETICS; METASTASIS; PATHOLOGY;

ANIMALS; ANIMALS, DOMESTIC; BONE NEOPLASMS; DOG DISEASES; DOGS; HUMANS; NEOPLASM METASTASIS; OSTEOSARCOMA;

EID: 77953662780     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0284-9_24     Document Type: Conference Paper

References (44)

1. Dernell WS, Ehrhart NP, Straw RC, et al. Tumors of the Skeletal System. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 4th ed. St Louis: Saunders Elsevier; 2007:540-582.
2. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008;8:147-156.
3. Withrow SJ, Powers BE, Straw RC, et al. Comparative aspects of osteosarcoma: dog vs. man. Clin Orthop. 1991;270:159-167.
4. Ru G, Terracini B, Glickman LT. Host related risk factors for canine osteosarcoma. Vet J. 1998;156:31-39.
5. Misdorp W, Hart AA. Some prognostic and epidemiological factors in canine osteosarcoma. J Natl Cancer Inst. 1979;62:537-545.
6. Gellasch KL, Kalscheur VL, Clayton MK, et al. Fatigue microdamage in the radial predilection site for osteosarcoma in dogs. Am J Vet Res. 2002;63(6):896-899.
7. Stevenson S, Holm RB, Pohler OEM, et al. Fracture-associated sarcoma in the dog. J Am Vet Med Assoc. 1982;180:1189.
8. Miller SC, Lloyd RD, Bruenger FW, et al. Comparisons of the skeletal locations of putative plutonium-induced osteosarcomas in humans with those in beagle dogs and with naturally occurring tumors in both species. Radiat Res. 2003;160(5):517-523.
9. White RG, Raabe OG, Culbertson MR, et al. Bone sarcoma characteristics and distribution in beagles injected with radium-226. Radiat Res. 1994;137(3):361-370.
10. McChesney-Gillette S, Gillette EL, Powers BE, et al. Radiation-induced osteosarcoma in dogs after external beam or intraoperative radiation therapy. Cancer Res. 1990;50:54-57.
11. Mayr B, Eschborn U, Loupal G, et al. Characterisation of complex karyotype changes in two canine bone tumours. Res Vet Sci. 1991;51(3):341-343.
12. Thomas R, Scott A, Langford CF, et al. Construction of a 2-Mb resolution BAC microarray for CGH analysis of canine tumors. Genome Res. 2005;15(12):1831-1837.
13. Campbell SE, Nasir L, Argyle DJ, et al. Cloning of canine IL-1ra, TNFR and TIMP-2. Vet Immunol Immunopathol. 2001;78(2):207-214.
14. Phillips JC, Stephenson B, Hauck M, et al. Heritability and segregation analysis of osteosarcoma in the Scottish deerhound. Genomics. 2007;90(3):354-363. Epub 2007 Jul 12.
15. Sagartz JE, Bodley WL, Gamblin RM, et al. p53 tumor suppressor protein overexpression in osteogenic tumors of dogs. Vet Pathol. 1996;33(2):213-221.
16. van Leeuwen IS, Cornelisse CJ, Misdorp W, et al. P53 gene mutations in osteosarcomas in the dog. Cancer Lett. 1997;111(1-2):173-178.
17. Levine RA. Overexpression of the sis oncogene in a canine osteosarcoma cell line. Vet Pathol. 2002;39(3):411-412.
18. MacEwen EG, Pastor J, Kutzke J, Tsan R, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem. 2004;92(1):77-91.
19. Owen LN. Transplantation of canine osteosarcoma. Eur J Cancer. 1969;5:615-620.
20. Wilson H, Huelsmeyer M, Chun R, et al. Isolation and characterisation of cancer stem cells from canine osteosarcoma. Vet J. 2008;175:69-75.
21. Barger AM, Fan TM, de Lorimier LP, et al. Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats. J Vet Intern Med. 2007;21(2):8.
22. Fan TM, de Lorimier LP, Charney SC. Urine N-telopeptide excretion in dogs with appendicular osteosarcoma. J Vet Intern Med. 2006;20(2):335-341.
23. Jankowski MK, Steyn PF, Lana SE, et al. Nuclear scanning with 99 m-Tc-HDP for the initial evaluation of osseous metastasis in canine osteosarcoma. Vet Comp Oncol. 2003;1:152-158.
24. Hillers KR, Dernell WS, Lafferty MHI, et al. Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986-2003). J Am Vet Med Assoc. 2005;226(8):1364-1367.
25. Ehrhart N, Dernell WS, Hoffmann WE, et al. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). J Am Vet Med Assoc. 1998;213:1002-1006.
26. Thrall DE, Withrow SJ, Powers BE, et al. Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: a dose response assay. Int J Rad Onc Biol Phys. 1990;18:1354-1357.
27. Farese JP, Milner R, Thompson MS, et al. Stereotactic radiosurgery for treatment of osteosarcomas involving the distal portions of the limbs in dogs. J Am Vet Med Assoc. 2004;225(10):1548, 1567-1572.
28. Straw RC, Withrow SJ. Limb-sparing surgery versus amputation for dogs with bone tumors. Vet Clin North Am. 1996;26:135-143.
29. Withrow SJ, Thrall DE, Straw RC, et al. Intra-arterial cisplatin with or without radiation in limbsparing for canine osteosarcoma. Cancer. 1993;71:2484-2490.
30. Powers BE, Withrow SJ, Thrall DE, et al. Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer. 1991;67:126-134.
31. Withrow SJ, Liptak J, Straw RC, et al. Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma. Ann Surg Oncol. 2004;11(7):705-713.
32. Berg J, Weinstein MJ, Springfield DS, et al. Response of osteosarcoma in the dog to surgery and chemotherapy with doxorubicin. J Am Vet Med Assoc. 1995;206(10):1555-1560.
33. Mauldin GN, Matus RE, Withrow SJ. Canine osteosarcoma treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Int Med. 1988;2:177-180.
34. Kent MS, Strom A, Strom A, London CA, et al. Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. J Vet Intern Med. 2004;18(4):540-544.
35. Withrow SJ, Straw RC, Brekke JH, et al. Slow release adjuvant cisplatin for the treatment of metastatic canine osteosarcoma. Eur J Musculoskel Res. 1995;4:105-110.
36. MacEwen EG, Kurzmann ID, Rosenthal RC. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989;81:935-938.
37. Lascelles BDX, Dernell WS, Correa MT, et al. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Annals of Surg Oncol. 2005;12(12):1073-1083.
38. MacEwen EG, Kutzke J, Carew J, et al. c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis. 2003;20(5):421-430.
39. Lana SE, Ogilvie GK, Hansen RA, et al. Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res. 2000;61(2):111-114.
40. Wergin MC, Kaser-Hotz B, Kaser-Hotz B. Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours. In Vivo. 2004;18(1):15-19.
41. Mullins MN, Lana SE, Dernell WS, et al. Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med. 2004;18(6):859-865.
42. Khanna C, Wan X, Bose S, et al. Ezrin, a Membrane - Cytoskeleton Linker, is Necessary for Osteosarcoma Metastasis. Nat Medicine. 2004;10(2):182-186.
43. Flint AF, U'Ren L, Legare ME, et al. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Vet Pathol. 2004;41(3):291-296.
44. O'Brien MG, Straw RC, Withrow SJ, et al. Resection of pulmonary metastases in canine osteosarcoma: 36 cases (1983-1992). Vet Surg. 1993;22:105-109.